1.The Korean Rectal Cancer Multidisciplinary Committee Clinical Practice Guidelines for Rectal Cancer version 2.0
Hyo Seon RYU ; Hyun Jung KIM ; Dong Hyun KANG ; Yoo-Kang KWAK ; Han Deok KWAK ; Yoon-Hye KWON ; Dalyon KIM ; Baek-Hui KIM ; Jae Hyun KIM ; Ji Hun KIM ; Jin Won KIM ; Tae Hyung KIM ; Hae Young KIM ; Soo Min NAM ; Gyoung Tae NOH ; Jun Woo BONG ; Nak Song SUNG ; Seon Hui SHIN ; Kil-Yong LEE ; Sung Chul LEE ; Sea-Won LEE ; Jung Won LEE ; Jong Min LEE ; Myung Hoon IHN ; Joo Han LIM ; Woong Bae JI ; Dae Hee PYO ; Young Ki HONG ; Jung-Myun KWAK ;
Annals of Coloproctology 2026;42(1):4-33
Rectal cancer, which accounts for approximately 40% of colorectal cancers, remains a major clinical concern. Recent advances in diagnostic imaging, surgical techniques, radiotherapy, and systemic treatment have steadily improved rectal cancer outcomes. Considering this, the Korean Rectal Cancer Multidisciplinary (KRCM) Committee has aimed to provide clinicians and policymakers with up-to-date, evidence-based clinical practice guidelines to support optimal decision-making, reflecting current evidence, the Korean healthcare context, and patient values and preferences. The Clinical Practice Guidelines for Rectal Cancer version 2.0 were developed through multidisciplinary collaboration with related academic societies, building upon and updating the KRCM Clinical Practice Guidelines version 1.0 (titled “Multidisciplinary guidelines for the management of rectal cancer”). These consensus guidelines of the KRCM were established based on a comprehensive literature review, evidence synthesis, with recommendation development guided by the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology, and consideration of applicability in real-world clinical practice under the national health insurance system. Each recommendation has been presented with its strength and level of evidence.
2.Clinical Efficacy and Scalp Microbiome Changes Induced by AMPamide-Containing Shampoo in Patients With Seborrheic Dermatitis
Yi Na YOON ; Sae Hee KIM ; Ji Won LIM ; Myeong Jae KIM ; Hye-Jin KIM ; Woo Jun SUL ; Daehwan KIM ; Wonseok JEONG ; Jeonghwan HWANG ; Da-Ae YU ; Yong Beom CHOE ; Yang Won LEE
Annals of Dermatology 2026;38(3):237-247
Background:
Seborrheic dermatitis (SD) is a chronic inflammatory scalp disorder associated with Malassezia dysbiosis and increased sebum production. AMPamide has been suggested to have anti-inflammatory and sebum-regulating effects, but its clinical efficacy and microbiome-modulating effects in SD remain unclear.
Objective:
To evaluate the clinical efficacy and scalp microbiome changes following 4 weeks of use of an AMPamide-containing shampoo in patients with SD.
Methods:
In this observational study, 30 patients with SD applied an AMPamide-containing shampoo for 4 consecutive weeks. Clinical outcomes, including sebum levels and overall severity scores, were assessed. Scalp bacterial and fungal communities were analyzed to evaluate α- and β-diversity and changes in Malassezia composition.
Results:
Treatment resulted in significant reductions in sebum levels and clinical severity scores, particularly in erythema, dandruff, and pruritus. Bacterial community composition remained largely stable, while fungal α-diversity increased, and β-diversity analysis revealed a decrease in the ratio of Malassezia restricta to Malassezia globosa.
Conclusion
AMPamide-containing shampoo was associated with improved clinical symptoms and a shift toward a more balanced fungal community composition in patients with SD, supporting its potential as a non-steroidal therapeutic option for SD.
3.Too Low From a Self-Blow: Diagnostic and Therapeutic Challenges in a Case of Hirata’s Syndrome
Tharsini Sarvanandan ; Ying Guat Ooi ; Jun Kit Khoo ; Tricia Lopez ; Nicholas Ken Yoong Hee ; Shireene Vethakkan ; Lee-Ling Lim ; Jeyakantha Ratnasingam ; Carolyn Chee ; Pavai Sthaneshwar ; Quan Hziung Lim
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):50-
Introduction:
Non-diabetic hypoglycemia in older adults warrants
careful evaluation across insulin-mediated and noninsulin-mediated causes. We present a challenging case of
insulin autoimmune syndrome (IAS; Hirata’s syndrome).
Case:
An 85-year-old female presented with severe hypoglycemia (capillary blood glucose [CBG] 1.8 mmol/L) with
reduced consciousness, preceded by 2 months of recurrent
dizziness relieved by food intake. Appetite and weight were
stable. Past medical history included stage 3 chronic kidney
disease and osteoporosis, but no diabetes. Medication
review revealed a recent 2-week course of traditional
supplement, long-term Neurobion®, but no agents with
recognized hypoglycemic potential. Physical examination
showed a moderately built elderly female with a body
mass index of 24.3 kg/m² and no Cushingoid features.
Recurrent hypoglycemia (CBG nadir 1.5 mmol/L) occurred
in both fasting and postprandial states, fulfilling Whipple’s
triad. Baseline investigations showed an estimated
glomerular filtration rate of 42 mL/min/1.73 m², AM
cortisol of 700 mmol/L, and unremarkable liver and thyroid
function tests. During a hypoglycemic episode (CBG 2.3
mmol/L), plasma insulin and C-peptide were inappropriately raised at 203.6 mU/L (reference interval [RI]: 3.0–
25.0) and 33 ng/mL (RI: 0.9–7.1), respectively, confirming
endogenous hyperinsulinemic hypoglycemia. Polyethylene
glycol precipitation showed 21% insulin recovery, raising
suspicion for an autoimmune cause. Elevated insulin
autoantibodies (175 AU/mL; RI <20) confirmed IAS.
Computed tomography of the abdomen and endoscopic
ultrasound excluded a pancreatic neuro-endocrine tumor.
Nutritional management comprising frequent low glycemic
index feeds and uncooked cornstarch was commenced.
Diazoxide 100 mg TDS caused fluid overload and severe
hyponatremia, while hypoglycemia persisted at lower doses, necessitating discontinuation. Subcutaneous octreotide 100 mg QID was required to control hypoglycemia.
Prednisolone 30 mg BD improved glycemic stability. Insulin
autoantibodies titer remained 175 AU/mL at 2 weeks;
reassessment was conducted at 4 weeks with consideration for biologics if persistent.
:
doses, necessitating discontinuation. Subcutaneous octreotide 100 mg QID was required to control hypoglycemia.
Prednisolone 30 mg BD improved glycemic stability. Insulin
autoantibodies titer remained 175 AU/mL at 2 weeks;
reassessment was conducted at 4 weeks with consideration for biologics if persistent.
Conclusion
Endogenous hyperinsulinemic hypoglycemia, after
excluding insulinoma, should raise suspicion for IAS.
Management includes removing triggers, supportive care,
and immunomodulatory therapy in severe cases.
4.Cold Spot Within a Hot Nodule: Thyroid Storm from Toxic Adenoma Revealing Rare Hurthle Cell Adenoma
Ying Guat Ooi ; Jun Kit Khoo ; Tharsini Sarvanandan ; Quan Hziung Lim ; Jeyakantha Ratnasingam ; Lee Ling Lim ; Shireene Ratna Vethakkan ; Nicholas Ken Yoong Hee
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):103-104
Introduction:
Hurthle cell adenoma is a rare benign thyroid neoplasm
that can only be diagnosed through histopathological
examination. Hurthle cell neoplasm typically presents as
nonfunctioning cold nodule on thyroid scintigraphy. We
report a rare case of Hurthle cell adenoma presenting with
thyroid storm, with unusual findings of “cold” within
“hot” thyroid nodule on scintigraphy.
Case:
A 73-year-old male with hypertension, chronic kidney
disease, coronary artery disease, and Parkinson’s disease
presented to the emergency department with fever and
diarrhea. His temperature was 38.4°C, heart rate 106 bpm,
and blood pressure 138/75 mmHg, with atrial fibrillation
and signs of heart failure. The Burch-Wartofsky score was
50, consistent with thyroid storm.
Laboratory tests revealed free thyroxine 4 37.8 pmol/L
(NR 11.5–22.7), free thyroxine 3 5.6 pmol/L (NR 3.5–6.5),
and thyroid-stimulating hormone <0.01 mIU/L (NR 0.55–
4.78). Thyroid autoantibodies, including anti-thyroid
peroxidase, anti-thyroglobulin, and thyroid-stimulating
immunoglobulins, were negative (<0.10 IU/L). The thyroid
storm was precipitated by invasive Klebsiella syndrome
with endophthalmitis and lung and liver abscess. He was
treated with Lugol’s iodine, corticosteroid, antibiotics, and
carbimazole.
Ultrasound thyroid revealed a mixed cystic-solid nodule
in the left thyroid lobe, measuring 2.3 × 3.3 × 4.3 cm (TIRADS category 3). Technetium-99m thyroid scintigraphy
demonstrated a hyperfunctioning left thyroid nodule with
a focal intranodular cold spot measuring 5.0 × 3.7 cm.
Fine needle aspiration cytology of the nodule was benign
follicular cells. Following stabilization with anti-thyroid
treatment, he underwent left hemithyroidectomy. Histopathology examination revealed a Hurthle cell adenoma
without capsular or vascular invasion.
Postoperatively, he remained clinically euthyroid. Surveillance ultrasound performed 8 months later showed a
normal right thyroid lobe, and lifelong surveillance was
planned.
Conclusion
This case illustrates a rare and unusual presentation of
thyroid storm caused by a toxic Hurthle cell adenoma
containing an intranodular cold spot on scintigraphy. To
our knowledge, only one similar case has been reported
in the literature, and our case is the first to present with
thyroid storm.
Oxyphil Cells
;
Thyroid Crisis
;
Adenoma
5.From Stability to Storm: Thyroid Storm After a Decade of Antithyroid Drug
Jun Kit Khoo ; Tharsini Sarvanandan ; Ying Guat Ooi ; Quan Hziung Lim ; Carolyn Wai Ling Chee ; Lee Ling Lim ; Jeyakantha Ratnasingam ; Shireene Ratna Vethakkan ; Nicholas Ken Yoong Hee
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):111-
Introduction:
Long-term antithyroid drug (LT-ATD) has emerged as
a feasible treatment strategy for patients who decline
radioactive iodine (RAI) or thyroidectomy for relapsed
or refractory Graves’ disease (GD). Benefits include
faster achievement of euthyroidism, lower risk of hypothyroidism, a more favorable cardiovascular profile, and
avoidance of surgical risks. Although fluctuations in
thyroid status may occur despite good compliance, thyroid
storm is exceedingly rare in patients on LT-ATD. While
there is no specific data on the incidence of thyroid storm
in this cohort, surveys suggest an overall low incidence
(0.2–0.76 cases per 100,000 annually). We report a patient
with stable GD who developed a thyroid storm despite
more than 10 years of LT-ATD.
Case:
A 40-year-old female was diagnosed with GD 11 years
earlier during pregnancy. Treatment was stopped at 25
weeks’ gestation, but she relapsed at 7 months postpartum
and was started on carbimazole. She declined RAI or
surgery following a relapse and remained on carbimazole
5–10 mg daily, with good compliance. She presented with
a 1-day history of fever, cough, rhinorrhea, diarrhea, and
palpitations. She was compliant with carbimazole 5 mg
daily. On presentation, BP was 132/70 mmHg, HR 140
bpm, temperature 38.5°C, and SpO2 98% on air. She was
alert without agitation, had a diffuse goiter, mild proptosis,
and conjunctival injection, with otherwise normal
findings. Electrocardiogram showed sinus tachycardia.
Laboratory investigations demonstrated mild transaminitis,
leukocytosis, markedly elevated free T4 (>154 pmol/L),
suppressed thyroid-stimulating hormone (<0.008 mIU/L),
and elevated thyroid-stimulating immunoglobulin (2.25 IU/L, reference <0.55). Thyroid function tests 1 month ago
was normal. Her Burch-Wartofsky score was 60, consistent
with thyroid storm, likely precipitated by upper respiratory
tract infection. She improved with treatment and was
discharged with carbimazole 30 mg daily with planned
tapering, subsequently agreeing to RAI as definitive
treatment.
Conclusion
Infection may trigger thyroid storm despite good
compliance with LT-ATD. Patients should be counselled
regarding this risk and advised to seek early medical
attention if thyrotoxic symptoms recur.
Antithyroid Agents
;
Thyroid Crisis
6.Perceptions of treatment, accompanying symptoms, and other problems in patients with chronic pain: a multicenter cross-sectional study in Korea
Jieun BAE ; Yun Hee LIM ; Sung Jun HONG ; Jae Hun JEONG ; Hey Ran CHOI ; Sun Kyung PARK ; Jung Eun KIM ; Jae Hun KIM
The Korean Journal of Pain 2025;38(1):69-78
Background:
Chronic pain significantly affects daily activities, mental health, and the interpersonal relationships of patients. Consequently, physicians use various treatments to manage pain. This study investigated the perceptions of treatment, accompanying symptoms, and other problems in patients with chronic pain.
Methods:
The authors enrolled patients with chronic pain from 19 university hospitals in South Korea. Data was collected on age, gender, diagnosis, disease duration, severity of pain, perception of pain treatment, and accompanying symptoms or problems using an anonymous survey comprising 19 questions.
Results:
In total, 833 patients with chronic pain completed the survey, and 257 (31.0%) and 537 (64.5%) patientsexpressed concerns about the potential adverse effects of medication and opioid addiction, respectively. Personalitychanges such as irritability or anger were the most frequent accompanying symptoms in 507 (63.8%) patients, followed by depression and sleep disturbance in 462 (58.1%) and 450 (54.5%) patients, respectively. Depression (P = 0.001) and anxiety (P = 0.029) were more common among women, whereas divorce (P = 0.016), family conflict (P < 0.001), unemployment (P < 0.001), suicide attempts (P < 0.001), and restrictions on economic activity (P < 0.001) were more common among men. The frequency of accompanying symptoms, except for suicidal ideation,was higher in the younger patients aged ≤ 40 years than in the older patients aged > 40 years.
Conclusions
Many patients with chronic pain had concerns about adverse effects or medication tolerance and experienced anxiety, depression, or sleep disturbances. The prevalence of accompanying problems varies according to age and gender.
7.Profiling of Anti-Signal-Recognition Particle Antibodies and Clinical Characteristics in South Korean Patients With Immune-Mediated Necrotizing Myopathy
Soo-Hyun KIM ; Yunjung CHOI ; Eun Kyoung OH ; Ichizo NISHINO ; Shigeaki SUZUKI ; Bum Chun SUH ; Ha Young SHIN ; Seung Woo KIM ; Byeol-A YOON ; Seong-il OH ; Yoo Hwan KIM ; Hyunjin KIM ; Young-Min LIM ; Seol-Hee BAEK ; Je-Young SHIN ; Hung Youl SEOK ; Seung-Ah LEE ; Young-Chul CHOI ; Hyung Jun PARK
Journal of Clinical Neurology 2025;21(1):31-39
Background:
and Purpose This study evaluated the diagnostic utility of an anti-signal-recognition particle 54 (anti-SRP54) antibody-based enzyme-linked immunosorbent assay (ELISA) as well as the clinical, serological, and pathological characteristics of patients with SRP immune-mediated necrotizing myopathy (IMNM).
Methods:
We evaluated 87 patients with idiopathic inflammatory myopathy and 107 healthy participants between January 2002 and December 2023. The sensitivity and specificity of the ELISA for anti-SRP54 antibodies were assessed, and the clinical profiles of patients with antiSRP54 antibodies were determined.
Results:
The ELISA for anti-SRP54 antibodies had a sensitivity and specificity of 88% and 99%, respectively, along with a test–retest reliability of 0.92 (p<0.001). The 32 patients diagnosed with anti-SRP IMNM using a line-blot immunoassay included 28 (88%) who tested positive for anti-SRP54 antibodies using the ELISA, comprising 12 (43%) males and 16 (57%) females whose median ages at symptom onset and diagnosis were 43.0 years and 43.5 years, respectively. Symptoms included proximal muscle weakness in all 28 (100%) patients, neck weakness in 9 (32%), myalgia in 15 (54%), dysphagia in 5 (18%), dyspnea in 4 (14%), dysarthria in 2 (7%), interstitial lung disease in 2 (7%), and myocarditis in 2 (7%). The median serum creatine kinase (CK) level was 7,261 U/L (interquartile range: 5,086–10,007 U/L), and the median anti-SRP54 antibody level was 2.0 U/mL (interquartile range: 1.0–5.6 U/mL). The serum CK level was significantly higher in patients with coexisting anti-Ro-52 antibodies.
Conclusions
This study has confirmed the reliability of the ELISA for anti-SRP54 antibodies and provided insights into the clinical, serological, and pathological characteristics of South Korean patients with anti-SRP IMNM.
8.Clinicopathological Correlations of Neurodegenerative Diseases in the National Brain Biobank of Korea
Young Hee JUNG ; Jun Pyo KIM ; Hee Jin KIM ; Hyemin JANG ; Hyun Jeong HAN ; Young Ho KOH ; Duk L. NA ; Yeon-Lim SUH ; Gi Yeong HUH ; Jae-Kyung WON ; Seong-Ik KIM ; Ji-Young CHOI ; Sang Won SEO ; Sung-Hye PARK ; Eun-Joo KIM
Journal of Clinical Neurology 2025;21(3):190-200
Background:
and Purpose The National Brain Biobank of Korea (NBBK) is a brain bank consortium supported by the Korea Disease Control and Prevention Agency and the Korea National Institute of Health, and was launched in 2015 to support research into neurodegenerative disease dementia (NDD). This study aimed to introduce the NBBK and describes clinicopathological correlations based on analyses of data collected from the NBBK.
Methods:
Four hospital-based brain banks have been established in South Korea: Samsung Medical Center Brain Bank (SMCBB), Seoul National University Hospital Brain Bank (SNUHBB), Pusan National University Hospital Brain Bank (PNUHBB), and Myongji Hospital Brain Bank (MJHBB). Clinical and pathological data were collected from these brain banks using standardized protocols. The prevalence rates of clinical and pathological diagnoses were analyzed in order to characterize the clinicopathological correlations.
Results:
Between August 2016 and December 2023, 185 brain specimens were collected and pathologically evaluated (SNUHBB: 117; PNUHBB: 27; SMCBB: 34; MJHBB: 7). The age at consent was 70.8±12.6 years, and the age at autopsy was 71.7±12.4 years. The four-most-common clinical diagnoses were Alzheimer’s disease (AD) dementia (20.0%), idiopathic Parkinson’s disease (15.1%), unspecified dementia (11.9%), and cognitively unimpaired (CU) (11.4%).Most cases of unspecified dementia had a pathological diagnosis of central nervous system (CNS) vasculopathy (31.8%) or AD (31.8%). Remarkably, only 14.2% of CU cases had normal pathological findings. The three-most-common pathological diagnoses were AD (26.5%), CNS vasculopathy (14.1%), and Lewy body disease (13.5%).
Conclusions
These clinical and neuropathological findings provide a deeper understanding of the mechanisms underlying NDD in South Korea.
9.Pulmonary Tumor Thrombotic Microangiopathy Associated With Gastric Cancer: Clinical Characteristics and Outcomes
Tae-Se KIM ; Soomin AHN ; Sung-A CHANG ; Sung Hee LIM ; Byung-Hoon MIN ; Yang Won MIN ; Hyuk LEE ; Poong-Lyul RHEE ; Jae J. KIM ; Jun Haeng LEE
Journal of Gastric Cancer 2025;25(2):276-284
Purpose:
Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal complication of gastric cancer (GC). This study aimed to evaluate the clinical characteristics, outcomes, and immunohistochemical profiles of patients with GC-induced PTTM.
Materials and Methods:
From 2011 to 2023, 8 patients were clinically diagnosed with PTTM associated with GC antemortem. Clinical features and outcomes were reviewed, and immunohistochemical staining for c-erbB-2, MutL protein homolog 1, and programmed cell death ligand-1 was performed.
Results:
The median patient age was 56 years (range, 34–66 years). In all the patients, the tumors exhibited either ulceroinfiltrative or diffusely infiltrative gross morphology.The median tumor size was 5.8 cm (range, 2.0 cm–15.0 cm). Poorly differentiated adenocarcinoma was the most common histological type (6/8, 75%), followed by signet ring cell carcinoma (1/8, 12.5%) and moderately differentiated adenocarcinoma (1/8, 12.5%).Chest computed tomography revealed ground-glass opacities (7/8, 87.5%) or tree-in-bud signs (2/8, 25.0%) without definite evidence of pulmonary thromboembolism. Disseminated intravascular coagulation was present in 62.5% (5/8) of the patients diagnosed with PTTM.C-erbB-2 was positive in one patient (1/8, 12.5%). One patient who received palliative chemotherapy after developing PTTM survived for 35 days, whereas the other 7 patients who did not receive chemotherapy after developing PTTM survived for 7 days or less after PTTM diagnosis.
Conclusions
Most patients with GC-induced PTTM had an undifferentiated-type histology, infiltrative morphology, and extremely poor survival. Palliative chemotherapy may benefit patients with GC-induced PTTM; however, further studies are needed to explore the potential of targeted therapy in these patients.
10.Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
In-Ho KIM ; Seung Joo KANG ; Wonyoung CHOI ; An Na SEO ; Bang Wool EOM ; Beodeul KANG ; Bum Jun KIM ; Byung-Hoon MIN ; Chung Hyun TAE ; Chang In CHOI ; Choong-kun LEE ; Ho Jung AN ; Hwa Kyung BYUN ; Hyeon-Su IM ; Hyung-Don KIM ; Jang Ho CHO ; Kyoungjune PAK ; Jae-Joon KIM ; Jae Seok BAE ; Jeong Il YU ; Jeong Won LEE ; Jungyoon CHOI ; Jwa Hoon KIM ; Miyoung CHOI ; Mi Ran JUNG ; Nieun SEO ; Sang Soo EOM ; Soomin AHN ; Soo Jin KIM ; Sung Hak LEE ; Sung Hee LIM ; Tae-Han KIM ; Hye Sook HAN ; On behalf of The Development Working Group for the Korean Practice Guideline for Gastric Cancer 2024
Journal of Gastric Cancer 2025;25(1):5-114
Gastric cancer is one of the most common cancers in both Korea and worldwide. Since 2004, the Korean Practice Guidelines for Gastric Cancer have been regularly updated, with the 4th edition published in 2022. The 4th edition was the result of a collaborative work by an interdisciplinary team, including experts in gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology, and guideline development methodology. The current guideline is the 5th version, an updated version of the 4th edition. In this guideline, 6 key questions (KQs) were updated or proposed after a collaborative review by the working group, and 7 statements were developed, or revised, or discussed based on a systematic review using the MEDLINE, Embase, Cochrane Library, and KoreaMed database. Over the past 2 years, there have been significant changes in systemic treatment, leading to major updates and revisions focused on this area.Additionally, minor modifications have been made in other sections, incorporating recent research findings. The level of evidence and grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation system. Key factors for recommendation included the level of evidence, benefit, harm, and clinical applicability. The working group reviewed and discussed the recommendations to reach a consensus. The structure of this guideline remains similar to the 2022 version.Earlier sections cover general considerations, such as screening, diagnosis, and staging of endoscopy, pathology, radiology, and nuclear medicine. In the latter sections, statements are provided for each KQ based on clinical evidence, with flowcharts supporting these statements through meta-analysis and references. This multidisciplinary, evidence-based gastric cancer guideline aims to support clinicians in providing optimal care for gastric cancer patients.


Result Analysis
Print
Save
E-mail